Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APTC-C-SA01
- Development stage
- Unknown
- Lead developer
- Adelaide Phage Therapy Centre
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intranasal, Topical
01
Overview
APTC-C-SA01 is an investigational biologic therapy comprising a cocktail of four lytic bacteriophages specifically isolated to target *Staphylococcus aureus*, including methicillin-resistant strains (MRSA). Developed by the Central Adelaide Local Health Network, this topical therapy is administered intranasally for the treatment of therapy-refractory chronic rhinosinusitis (CRS). The phages function by binding to the bacterial cell wall, injecting their genetic material, and inducing lysis of the host bacteria, which effectively reduces bacterial load and disrupts recalcitrant biofilms. It has been evaluated in investigator-initiated clinical trials to assess its safety and efficacy in patients who have failed standard medical and surgical treatments.
- Other names
- topical bacteriophage cocktailS. aureus phage cocktail
02
Targets
SpA (Staphylococcal protein A)
Beyond the preview
Go deeper on APTC-C-SA01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APTC-C-SA01.